These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Ligand-induced changes in the structure and dynamics of Escherichia coli peptide deformylase. Amero CD; Byerly DW; McElroy CA; Simmons A; Foster MP Biochemistry; 2009 Aug; 48(32):7595-607. PubMed ID: 19627112 [TBL] [Abstract][Full Text] [Related]
23. Ligand and Structure-Based Approaches for the Identification of Peptide Deformylase Inhibitors as Antibacterial Drugs. Gao J; Liang L; Zhu Y; Qiu S; Wang T; Zhang L Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27428963 [TBL] [Abstract][Full Text] [Related]
24. Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. Lee MD; She Y; Soskis MJ; Borella CP; Gardner JR; Hayes PA; Dy BM; Heaney ML; Philips MR; Bornmann WG; Sirotnak FM; Scheinberg DA J Clin Invest; 2004 Oct; 114(8):1107-16. PubMed ID: 15489958 [TBL] [Abstract][Full Text] [Related]
25. Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Chen DZ; Patel DV; Hackbarth CJ; Wang W; Dreyer G; Young DC; Margolis PS; Wu C; Ni ZJ; Trias J; White RJ; Yuan Z Biochemistry; 2000 Feb; 39(6):1256-62. PubMed ID: 10684604 [TBL] [Abstract][Full Text] [Related]
26. Peptide deformylase inhibitors with non-peptide scaffold: synthesis and structure-activity relationships. Lee SK; Choi KH; Lee SJ; Lee JS; Park JY; Kim BM; Lee BJ Bioorg Med Chem Lett; 2011 Jan; 21(1):133-6. PubMed ID: 21146987 [TBL] [Abstract][Full Text] [Related]
27. Mechanism of time-dependent inhibition of polypeptide deformylase by actinonin. Van Aller GS; Nandigama R; Petit CM; DeWolf WE; Quinn CJ; Aubart KM; Zalacain M; Christensen SB; Copeland RA; Lai Z Biochemistry; 2005 Jan; 44(1):253-60. PubMed ID: 15628866 [TBL] [Abstract][Full Text] [Related]
28. Identification of novel potent hydroxamic acid inhibitors of peptidyl deformylase and the importance of the hydroxamic acid functionality on inhibition. Thorarensen A; Deibel MR; Rohrer DC; Vosters AF; Yem AW; Marshall VD; Lynn JC; Bohanon MJ; Tomich PK; Zurenko GE; Sweeney MT; Jensen RM; Nielsen JW; Seest EP; Dolak LA Bioorg Med Chem Lett; 2001 Jun; 11(11):1355-8. PubMed ID: 11378353 [TBL] [Abstract][Full Text] [Related]
29. Isoxazole-3-hydroxamic acid derivatives as peptide deformylase inhibitors and potential antibacterial agents. Calí P; Naerum L; Mukhija S; Hjelmencrantz A Bioorg Med Chem Lett; 2004 Dec; 14(24):5997-6000. PubMed ID: 15546716 [TBL] [Abstract][Full Text] [Related]
30. Characterization of peptide deformylase2 from B. cereus. Park JK; Kim KH; Moon JH; Kim EE J Biochem Mol Biol; 2007 Nov; 40(6):1050-7. PubMed ID: 18047803 [TBL] [Abstract][Full Text] [Related]
31. Design and synthesis of macrocyclic peptidyl hydroxamates as peptide deformylase inhibitors. Shen G; Zhu J; Simpson AM; Pei D Bioorg Med Chem Lett; 2008 May; 18(10):3060-3. PubMed ID: 18093832 [TBL] [Abstract][Full Text] [Related]
32. 2D-QSAR in hydroxamic acid derivatives as peptide deformylase inhibitors and antibacterial agents. Gupta MK; Mishra P; Prathipati P; Saxena AK Bioorg Med Chem; 2002 Dec; 10(12):3713-6. PubMed ID: 12413827 [TBL] [Abstract][Full Text] [Related]
33. Structural basis for the design of antibiotics targeting peptide deformylase. Hao B; Gong W; Rajagopalan PT; Zhou Y; Pei D; Chan MK Biochemistry; 1999 Apr; 38(15):4712-9. PubMed ID: 10200158 [TBL] [Abstract][Full Text] [Related]
34. Understanding the highly efficient catalysis of prokaryotic peptide deformylases by shedding light on the determinants specifying the low activity of the human counterpart. Fieulaine S; Desmadril M; Meinnel T; Giglione C Acta Crystallogr D Biol Crystallogr; 2014 Feb; 70(Pt 2):242-52. PubMed ID: 24531459 [TBL] [Abstract][Full Text] [Related]
35. An improved crystal form of Plasmodium falciparum peptide deformylase. Robien MA; Nguyen KT; Kumar A; Hirsh I; Turley S; Pei D; Hol WG Protein Sci; 2004 Apr; 13(4):1155-63. PubMed ID: 15010544 [TBL] [Abstract][Full Text] [Related]
36. Crystallization and preliminary crystallographic analysis of creatininase from Pseudomonas putida. Beuth B; Niefind K; Schomburg D Acta Crystallogr D Biol Crystallogr; 2002 Aug; 58(Pt 8):1356-8. PubMed ID: 12136154 [TBL] [Abstract][Full Text] [Related]
37. Structures of Staphylococcus aureus peptide deformylase in complex with two classes of new inhibitors. Lee SJ; Lee SJ; Lee SK; Yoon HJ; Lee HH; Kim KK; Lee BJ; Lee BI; Suh SW Acta Crystallogr D Biol Crystallogr; 2012 Jul; 68(Pt 7):784-93. PubMed ID: 22751663 [TBL] [Abstract][Full Text] [Related]
38. Discovery and refinement of a new structural class of potent peptide deformylase inhibitors. Boularot A; Giglione C; Petit S; Duroc Y; Alves de Sousa R; Larue V; Cresteil T; Dardel F; Artaud I; Meinnel T J Med Chem; 2007 Jan; 50(1):10-20. PubMed ID: 17201406 [TBL] [Abstract][Full Text] [Related]
39. Characterization of a human peptide deformylase: implications for antibacterial drug design. Nguyen KT; Hu X; Colton C; Chakrabarti R; Zhu MX; Pei D Biochemistry; 2003 Aug; 42(33):9952-8. PubMed ID: 12924944 [TBL] [Abstract][Full Text] [Related]
40. Crystals of peptide deformylase from Plasmodium falciparum reveal critical characteristics of the active site for drug design. Kumar A; Nguyen KT; Srivathsan S; Ornstein B; Turley S; Hirsh I; Pei D; Hol WG Structure; 2002 Mar; 10(3):357-67. PubMed ID: 12005434 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]